VASO Restructures to Focus on Congestive Heart Failure
More News related to VASO
- Vasomedical Inc. (VASO) Announces Resignation of CFO, Company Names Tricia Efstathiou as Replacement
- Vasomedical (VASO) Anticipates Trading on Bulletin Board
- Vasomedical Inc. (VASO) Reports A Q3 Loss of $0.01
- Earnings Due Out After The Close Today & Before The Open Monday 04.17.06
- VASO Restructures to Focus on Congestive Heart Failure
More News related to Corporate News
- Transocean (RIG) Promotes Saltiel to EVP and COO
- Travelzoo (TZOO) Names Chris Loughlin to CEO, Effective July 2010
- Sysco Corp. (SYY) Names Twila Day to SVP and CIO
- NexMed (NEXM) Names Bassam Damaj to CEO, Will Replace Liu - DJN
- UTEK (UTK) Names President Schaedler to CEO
Vasomedical, Inc. (NASDAQ: VASO) announced an initiative to improve alignment of operations to pursue the congestive heart failure market. This initiative, which includes a workforce reduction plus tighter expense control, is expected to provide a clear focus on CHF investment and to reduce expenses by approximately $3 million over the next year.
Related Categories
Corporate NewsStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
